

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Blackburn, George L.		POSITION TITLE S. Daniel Abraham Associate Professor of Nutrition/Harvard Medical School	
eRA COMMONS USER NAME GBLACKBU			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Kansas, Lawrence, Kansas	B.A.	1958	Chemistry
Kansas Medical School, Kansas City	M.D.	1965	Medicine
Mass. Institute of Technology	Ph.D.	1973	Nutritional Biochemistry

Positions and Honors

- 1970 – 1973 NIH Postdoctoral Trainee, Nutrition & Food Science Department, Massachusetts Institute of Technology, Cambridge, MA
- 1973 – 1976 Assistant (1973), Associate (1976) Professor of Surgery, Harvard Medical School; Associate Surgeon, New England Deaconess Hospital, Boston, MA
- 1974- Surgeon, Active Staff, Beth Israel Deaconess Medical Center (BIDMC), Boston, MA
- 1976- Chief, Nutrition/Metabolism Laboratory, BIDMC, Boston, MA
- 1976 – 2001 Director, Nutrition Support Service, BIDMC, Boston, MA
- 1989- Director, Center for the Study of Nutrition Medicine, Deaconess Hospital, HMS
- 1995- Member, Nutrition Curriculum Committee, Harvard Medical School, Boston, MA
- 1997- Associate Director, Division of Nutrition, Harvard Medical School, Boston, MA
- 1997 – 2004 President, American Society of Clinical Nutrition (ASCN); 1998-1999 President, American Board of Nutrition (ABN); 1998-1999 President, North American Association for the Study of Obesity (NAASO) Associate Director, NIH Boston Obesity Nutrition Research Center (BONRC)
- 2004 Vice-Chair Comm. Of MA Betsy Lehman Center for Patient Safety and Medical error reduction Expert Panel on Weight Loss Surgery
- 1994 – 1996 Member of NIH Study Sections on: Non-Insulin Dependent Diabetes Primary Prevention Trial; Clinical Trials in Minority Health; Clinical Trials in Native American Health; Co-Chairman, NCI Hereditary Cancer Workshop – Colon 1997 Member, NIH Behavioral Medicine Study Section 2001NIH NIDDK Special Emphasis panel,2003 LT Cancer Survivors Review Committee, 2004 NIH SEP grant review SSS-U (03),2005 CNRU Council ZDK1 GRB-1 M2 Reviewer
- Honors:** Alpha Omega Alpha, Junior Year (1964); Grace Goldsmith Award, American College of Nutrition (1985); Joseph B. Goldberger Award in Clinical Nutrition, American Medical Association (1998) Fellow American Society for Nutritional Sciences (2004).

Board Certifications

- 1966 Massachusetts License Registration; 1972 American Board of Surgery
- 1973 American Board of Nutrition

Selected Publications (from a list of 404 original scientific articles).

1. Bistran BR, **Blackburn GL**, Scrimshaw NS, Flatt JP. Cellular immunity in semistarved states in hospitalized adults. *Am J Clin Nutr* 1975; 28:1148-1155.
2. Bistran BR, **Blackburn GL**, Flatt JP, Sizer J, Scrimshaw NS, Sherman M. Nitrogen metabolism and insulin requirements in obese diabetic adults on protein-sparing modified fast. *Diabetes* 1976; 25:494-504.
3. **Blackburn GL**, Greenberg I. Multidisciplinary approach to adult obesity therapy. *Int J Obes* 1978;2:133-142.
4. Merritt RJ, Bistran BR, **Blackburn GL**, Suskind RM. Consequences of modified fasting in obese pediatric and adolescent patients. I, Protein sparing modified fast. *J Pediatr* 1980; 96:13-19.

5. Bern MM, Bothe A Jr, Bistrrian BR, Batist G, Hayward E, **Blackburn GL**. Effects of low-dose warfarin on antithrombin III levels in patients morbidly obese. *Surgery* 1983; 94:78-83.
6. Yang RD, Moldawer LL, Sakamoto A, Keenan RA, Matthews DE, Wolfe RR, Young VR, Wannemacher RW Jr, **Blackburn GL**, Bistrrian BR. Leukocyte endogenous mediator alters protein dynamics in rats. *Metabolism* 1983; 32:6454-6460.
7. Phinney SD, Bistrrian BR, Evans WJ, Gervino E, **Blackburn GL**. The human metabolic response to chronic ketosis without caloric restriction: Preservation of submaximal exercise capability with reduced carbohydrate oxidation. *Metabolism* 1983; 32:769-776.
8. Batist G, Bothe A Jr, Bern M, Bistrrian BR, **Blackburn GL**. Low antithrombin III in morbid obesity: Return to normal with weight reduction. *JPEN* 1983; 7:447-449.
9. **Blackburn GL**, Wilson GT, Kanders BS, Stein LJ, Lavin PT, Adler J, Brownell KD. Weight cycling: The experience of human dieters. *Am J Clin Nutr* 1989; 49:1105-9.
10. **Blackburn GL**, Morgan JP, Lavin PT, Noble R, Funderburk FR, Istfan NW. Determinants of the pressor effect of phenylpropanolamine in healthy subjects. *JAMA* 1989; 261:3267-72.
11. Flores EA, Drabik M, Gauldie J, **Blackburn GL**, Dinarello CA, Bistrrian BR. Leukocyte endogenous mediator fails to alter protein dynamics in a model of liver dysfunction. *J Lab Clin Med* 1989; 113:211-20.
12. Benotti PN, Bistrrian B, Benotti JR, **Blackburn G**, Forse RA. Heart disease and hypertension in severe obesity: the benefits of weight reduction. *Am J Clin Nutr*, Feb, 1992; 55(2 Suppl): 586S-590S.
13. Istfan NW, Plaisted CS, Bistrrian BR, **Blackburn GL**. Insulin resistance versus insulin secretion in the hypertension of obesity. *Hypertension* 1992; 19:385-92.
14. Whatley JE, Gillespie WJ, Honig J, Walsh MJ, Blackburn AL, **Blackburn GL**. Does the amount of endurance exercise in combination with weight training and a very-low-energy diet affect resting metabolic rate and body composition? *Am J Clin Nutr* 1994; 59 (5):1088-92.
15. Kanders BS, Ullmann-Joy, P, Foreyt JP, Heymsfield SB, Heber D, Elashoff, > RM, Ashley JM, Reeves RS, **Blackburn GL**. The black American lifestyle intervention (BALI): the design of a weight loss program for working-class African-American women. *JADA*, 1994, 94:310-312.
16. Bray GA, **Blackburn GL**, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. *Obes Res* 1999; 7:189-198.
17. Grundy SM, **Blackburn G**, Higgins M, Lauer R, Perri MG, Ryan D. Physical activity in the prevention and treatment of obesity and its comorbidities: evidence report of independent panel to assess the role of physical activity in the treatment of obesity and its comorbidiities. *Med Sci Sports Exerc* 1999; 31(11): 1493-1500.
18. Burger AJ, Charlamb MJ, Singh S, Notarianni M, **Blackburn GL**, Sherman HB. Low risk of significant echocardiographic valvulopathy in patients threated with anorectic drugs. *Int J Cardiol* 2001; 79:159-65.
19. Mun EC, **Blackburn GL**, Matthews JB. Current status of medical and surgical therapy for obesity. *Gastroenterology* 2001;120:669-681.
20. Zhou JR, Yu L, Zhong Y, **Blackburn GL**. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. *J Nurt* 2003;133:516-521.
21. Yu L, **Blackburn GL**, Zhou JR. Genistein and daidzein down-regulate androgen-regulated transcript-1 (PART-1) gene expression induced by 5a-dihydrotestosterone in human prostate LNCaP cancer cells. *J Nutr* 2003;133:389-392.
22. **Blackburn GL**. National Health and Nutrition Examination Survery: where nutrition meets medicine for the benefit of health. *Am J Clin Nutr* 2003; 78:197-198.
23. Winters BL, Mitchell DC, Wright H, Grosvenor M, Liu W, **Blackburn GL**. Dietary patterns in women treated for breast cancer who successfully reduced fat intake: The Women's Intervention Nutrition Study (WINS). *J Am Diet Assoc*. 2004; 104:551-559.
24. **Blackburn GL**, Hu FB, Harvey AM. Evidence-based recommendations for best practices in weight loss surgery. *Obes Res*. 2005; 13:203-204.
25. Chlebowski RT, **Blackburn GL**, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. *J Natl Cancer Inst*. 2006;98:1767-76.

C. Research Support

Active

DK57154-07 (D. Nathan, PI)

NIDDK

09/01/01-08/18/07

The Study of Health Outcomes of Weight Loss

The major goals of this project are to 1) determine whether intensive therapies directed at achieving and maintaining weight loss in moderately overweight persons with Type 2 diabetes affect a variety of long-term outcomes known to be sensitive to obesity when compared with a control group that is managed according to community standards.

Role: Co-Investigator

RO1 (1RO1 CA92546-01A2) (Zhou, PI)

NCI/NIH

06/01/2003-05/31/2007

“Chemoprevention of Bladder Cancer by Soybean bioactive components” (To investigate the role of soy bioactive components in bladder cancer prevention)

The major goal of this project is to investigate the effects of a series of soybean components, such as soy isoflavone genistein, soy protein isolate, and soy phytochemical extracts, on the growth and metastasis of bladder cancer in animal models.

Role: Co-Investigator

7R01-CA045504-17 (Chlebowski PI)

NCI

09/30/88 – 12/31/06

Low-Fat Diet in Stage II Breast Cancer: Outcome Trial

The major goal of the project is to test that low fat diet will reduce disease recurrence and increase patient survival for post-menopausal women with localized breast cancer

Role: Co- PI

Completed Research Support

RO1 CA105204-02 (McTiernan, PI)

NCI/NIH

10/01/03-06/30/06

Exercise, Diet, and Sex Hormones in Postmenopausal women

The major goal of this study will be to examine the effect of weight reduction through diet and exercise on breast cancer biomarkers in postmenopausal women.

Role: Co-Investigator

Nichimo (Ricciotti, PI)

6/03/02 – 6/24/06

Effects of Soy Isoflavones on Menopausal Hot Flashes

The Major goal of this study is to determine the effect of a novel daidzein rich isoflavone aglycone extract from soy germ on hot flash frequency and severity in menopausal women.

Role: Co-PI

Beverage Institute of Health and Wellness (Blackburn, PI)

12/01/04 – 11/20/06

Regular Orange Juice – Calcium and Weight Management

Principal Investigator/Program Director (Last, First, Middle):

The primary goal of this study is to evaluate the effect of calcium and vitamin D supplementation in the form of calcium and vitamin D fortified orange juice beverage in combination with caloric deficit diet on weight loss in overweight and obese adults.

Role: PI

Beverage Institute of Health and Wellness (Blackburn, PI)

12/01/04 – 11/20/06

Lite Orange Juice – Calcium and Weight Management

The primary goal of this study is to evaluate the effect of calcium and vitamin D supplementation in the form of calcium and vitamin D fortified orange juice beverage in combination with caloric deficit diet on weight loss in overweight and obese adults.

Role: PI

5R01-CA45504-15 (Nixon, PI)

AHF/NCI

01/01/97 – 12/31/04

Low-Fat Diet in Stage II Breast Cancer: Outcome Trial

The major goal of the project is to test that low fat diet will reduce disease recurrence and increase patient survival for post-menopausal women with localized breast cancer

Role: Co-Investigator/Nutrition Committee Chair

RO1 (1R01AT00863) (Zhou, PI)

NCCAM/NIH

09/12/2001-05/31/2004

“Interaction between dietary soy components and tamoxifen on breast cancer progression”

The major goals of this project are to investigate the combined effects of soy components and tamoxifen on the progression of estrogen-dependent, tamoxifen-resistant, and estrogen-independent breast cancer and the underlying mechanisms. Dr. Zhou is the PI in this project and is responsible for experimental design, data analysis and manuscript preparation.

Role: Co-Investigator

Atkins Foundation (Blackburn, PI)

06/01/01-05/30/03

Comparison of weight loss dietary strategies: low carbohydrate ketogenic diets compared with low fat diet

GlaxoSmithKlein (Blackburn, PI)

6/03/02-6/03/03

An Eight-Week, Parallel Group, Double-Blind, Randomized, Placebo and Active-Controlled, Multicenter Study to Evaluate the Efficiency, Safety and Tolerability of Two Formulations of GI181771X, Each a Two Different Doses in Obese Subjects.

Nichimo Co. (Zhou, PI)

03/01/01 – 05/31/03

Effects of AglyMax on the prevention and treatment of obesity and prostate cancer

The major goals of this proposal are to evaluate the effects of a soy isoflavone aglycone mixture on the prevention and treatment of weight gain and prostate cancer.

Role: Co-Investigator